New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
08:30 EDTBAYRYFDA says data doesn't support aspirin as defense against first heart attack
The FDA stated in a consumer information communication issued May 2 that it has reviewed the available data and does not believe the evidence supports the general use of aspirin for primary prevention of a heart attack or stroke. "In fact, there are serious risks associated with the use of aspirin, including increased risk of bleeding in the stomach and brain, in situations where the benefit of aspirin for primary prevention has not been established," the FDA said. The available evidence supports the use of aspirin for preventing another heart attack or stroke in patients who have cardiovascular disease or who have already had a heart attack or stroke, the FDA added, stating that the known benefits of aspirin for secondary prevention outweigh the risk of bleeding in patients who have had a cardiovascular event. “Importantly, the ruling does not impact the numerous cardiovascular indications for which aspirin is already approved by the FDA,” Anne Coiley, a spokeswoman for Bayer, said in an e-mail to Bloomberg. Reference Link
News For BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
09:32 EDTBAYRYFoamix says FDA approves Finacea Foam 15% for mild to moderate rosacea
As announced by Bayer HealthCare (BAYRY), the U.S. FDA has approved Finacea Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Papulopustular rosacea is a skin disease causing inflammatory lesions on the nose, cheeks, chin and forehead. Finacea Foam was developed as part of a research and development collaboration between Foamix Pharmaceuticals Ltd. (FOMX) and Bayer HealthCare, utilizing Foamix's proprietary foam technology platform. According to a license agreement between the two companies, Foamix is entitled to royalties and certain milestone payments upon commercialization of Finacea Foam. Finacea Foam will be available by prescription beginning in September, and will be marketed in the United States by Bayer HealthCare.
July 29, 2015
05:47 EDTBAYRYBayer cuts FY15 sales to EUR 47B from EUR 48B- EUR 49B
Subscribe for More Information
05:42 EDTBAYRYBayer reports Q2 Healthcare sales up 28% to EUR 5.91B
Subscribe for More Information
05:40 EDTBAYRYBayer reports Q2 net income EUR 1.52B vs. EUR 953M last year
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use